Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Trastornos del Movimiento

3520 ARTÍCULOS , VIENDO DEL 1396 AL 1410

Pilot study assessing the feasibility of applying bilateral subthalamic nucleus deep brain stimulation in very early stage Parkinson's disease: study design and rationale

Charles D, Tolleson C, Davis TL, Gill CE, Molinari AL, Bliton MJ, Tramontana MG, Salomon RM, Kao C, Wang L, Hedera P, Phibbs FT, Neimat JS, Konrad PE.

J Parkinsons Dis. 2012;2(3):215-23. doi: 10.3233/JPD-2012-012095.

Loss of functional alpha-synuclein: a toxic event in Parkinson's disease?

Kanaan NM, Manfredsson FP.

J Parkinsons Dis. 2012;2(4):249-67. doi: 10.3233/JPD-012138.

Sustained response to deep brain stimulation in LRRK2 parkinsonism with the Y1699C mutation

Perju-Dumbrava LD, McDonald M, Kneebone AC, Long R, Thyagarajan D.

J Parkinsons Dis. 2012;2(4):269-71. doi: 10.3233/JPD-012121.

Plasma-based circulating MicroRNA biomarkers for Parkinson's disease

Khoo SK, Petillo D, Kang UJ, Resau JH, Berryhill B, Linder J, Forsgren L, Neuman LA, Tan AC.

J Parkinsons Dis. 2012;2(4):321-31. doi: 10.3233/JPD-012144.

Difference in MSA phenotype distribution between populations: genetics or environment?

Ozawa T, Revesz T, Paviour D, Lees AJ, Quinn N, Tada M, Kakita A, Onodera O, Wakabayashi K, Takahashi H, Nishizawa M, Holton JL.

J Parkinsons Dis. 2012;2(1):7-18. doi: 10.3233/JPD-2012-11056.

Vibration therapy for Parkinson's disease: Charcot's studies revisited

Kapur SS, Stebbins GT, Goetz CG.

J Parkinsons Dis. 2012;2(1):23-7. doi: 10.3233/JPD-2012-12079.

The integrative care of Parkinson's disease: a systematic review

Prizer LP, Browner N.

J Parkinsons Dis. 2012;2(2):79-86. doi: 10.3233/JPD-2012-12075.

Cognitive behavioral therapy for depression and anxiety in Parkinson's disease: a clinical review

Armento ME, Stanley MA, Marsh L, Kunik ME, York MK, Bush AL, Calleo JS.

J Parkinsons Dis. 2012;2(2):135-51. doi: 10.3233/JPD-2012-12080.

[Vitamin D. A geriatric updated perspective]

Ribera Casado JM.

An R Acad Nac Med (Madr). 2012;129(1):319-40; discussion 340-1.

Investigational agents in the treatment of Parkinson's disease: focus on safinamide

Malek NM, Grosset DG.

J Exp Pharmacol. 2012 Aug 14;4:85-90. doi: 10.2147/JEP.S34343. eCollection 2012.

Cognitive assessment instruments in Parkinson's disease patients undergoing deep brain stimulation

Romann AJ, Dornelles S, Maineri NL, Rieder CRM, Olchik MR.

Dement Neuropsychol. 2012 Jan-Mar;6(1):2-11. doi: 10.1590/S1980-57642012DN06010002.

From small to big molecules: how do we prevent and delay the progression of age-related neurodegeneration?

Ho YS, Poon DC, Chan TF, Chang RC.

Curr Pharm Des. 2012;18(1):15-26. doi: 10.2174/138161212798919039.

Immunopathogenesis of neurodegenerative diseases: current therapeutic models of neuroprotection with special reference to natural products

Magrone T, Marzulli G, Jirillo E.

Curr Pharm Des. 2012;18(1):34-42. doi: 10.2174/138161212798919057.

Fermented grape marc (FGM): immunomodulating properties and its potential exploitation in the treatment of neurodegenerative diseases

Marzulli G, Magrone T, Kawaguchi K, Kumazawa Y, Jirillo E.

Curr Pharm Des. 2012;18(1):43-50. doi: 10.2174/138161212798919011.

Neuroprotective effects of lutein in the retina

Ozawa Y, Sasaki M, Takahashi N, Kamoshita M, Miyake S, Tsubota K.

Curr Pharm Des. 2012;18(1):51-6. doi: 10.2174/138161212798919101.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias